RNA Therapeutics market is poised to grow at a significant rate due to an increase in the prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries,  rise in funding for the development of RNA therapeutics from public and private sectors, promising pipeline drugs, and wide range of applications with RNA therapeutics are the major factors that are driving the growth of the global RNA therapeutics market over the forecast timeframe. Players focusing on innovation of newer products and collaboration strategies to retain market position in global RNA therapeutics market. For instance, In August 2018, US Food and Drug Administration approved the first RNA interference (RNAi) therapeutic, a treatment for polyneuropathy caused by transthyretin (TTR) amyloidosis from Alnylam Pharmaceuticals. The report gives comprehensive outlook on RNA therapeutics across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report gives historical, current, and future market sizes (US$ Mn) on the basis of technology, application, route of administration, end user, and region. This report studies market dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA therapeutics products.